Reducing reliance on corticosteroids with rituximab: renewed hope for adult-onset patients with relapsing nephrotic syndrome
Osaka, Japan – One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. However, what about patients who developed nephrotic syndrome in adulthood? As this drug is not yet approved for use in adult-onset patients, researchers from Japan wanted to highlight the profound benefits that rituximab has in adult-onset patients with these challenging conditions. Nephrotic syndrome is a kidney disorder that causes the body to excrete too much protein in the urine. This condition can lead to edema, weight gain, and an increased risk of infections. ...
Read the release